Retrospective Analysis of Response Markers and Adverse Events in a Nationwide Cohort of Advanced Melanoma Patients Treated With Pembrolizumab
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Feb 2019.
- 20 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2019.